Blog
RSS FeedPosted by Michael Wonder on 06 Aug 2018
Glatect, alternative to Copaxone, added to public health plans of 5 Canadian provinces
6 August 2018 - Pendopharm’s Glatect (glatiramer acetate injection), a lower cost alternative to Teva’s Copaxone, has been added to ...
Posted by Michael Wonder on 01 Aug 2018
Canada’s drug agency advised against reimbursing a costly eczema drug — here’s why people are worried
30 July 2018 - Five years ago, Felix Tang’s eczema was a debilitating accompaniment to stress. The chronic inflammatory skin ...
Posted by Michael Wonder on 24 Jul 2018
Cystic fibrosis patients launch class-action suit over access to costly drug
24 July 2018 - A young Victoria woman with cystic fibrosis who fought to get coverage of a life-changing drug ...
Posted by Michael Wonder on 24 Jul 2018
Debunking the myths about a Canadian pharmacare program
24 July 2018 - A national pharmacare program may one day be a reality in Canada. Myths abound about how it ...
Posted by Michael Wonder on 23 Jul 2018
Proposed PMPRB changes could limit Canada’s access to new drugs
20 July 2018 - While the federal government’s proposed amendments to Canada’s patented medicines regulations are aimed at reducing the ...
Posted by Michael Wonder on 10 Jul 2018
Sanofi denounces CADTH negative recommendation on Dupixent
10 July 2018 - Sanofi Genzyme said that it is disappointed with the recent recommendation by CADTH to not reimburse Dupixent, ...
Posted by Michael Wonder on 09 Jul 2018
CADTH publishes final CDEC recommendation for dupilumab
9 July 2018 - CADTH has completed its assessment of Dupixent (dupilumab) for the treatment of patients with atopic dermatitis. ...
Posted by Michael Wonder on 05 Jul 2018
B.C. charity fights feds for access to life-saving medicine
5 July 2018 - Cure SMA Canada is urging the federal government to reimburse the costs of Spinraza. ...
Posted by Michael Wonder on 02 Jul 2018
Is nudging biologic patients towards biosimilars a good choice for plan sponsors?
29 June 2018 - A recent study examining the potential savings determined that, based on the uptake of available biosimilars ...
Posted by Michael Wonder on 28 Jun 2018
High cost specialty drugs continue to dominate the new drug landscape
26 June 2018 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilisation Information System research initiative, ...
Posted by Michael Wonder on 27 Jun 2018
New from CADTH: procedural guidelines and a streamlined therapeutic review framework
27 June 2018 - Recent changes continue to strengthen the Pharmaceutical Reviews portfolio and help CADTH adapt quickly to the changing ...
Posted by Michael Wonder on 17 Jun 2018
Drug patents could be Canada's special weapon in U.S. trade dispute
16 June 2018 - Taking an 'asymmetrical' approach and targeting U.S. intellectual property has worked in the past, experts say. ...
Posted by Michael Wonder on 14 Jun 2018
From EpiPens to antibiotics, report finds Canada's drug shortages could be getting worse
13 June 2018 - Researchers find 1 in 10 drugs sold in Canada are back-ordered or discontinued. ...
Posted by Michael Wonder on 12 Jun 2018
85% of Canadians now have publicly funded access to a potentially life-extending treatment for patients with rare lung disease
12 June 2018 - Patients living in Alberta, Saskatchewan, Manitoba, Ontario and Newfoundland and Labrador are hopeful Uptravi will soon be ...
Posted by Michael Wonder on 07 Jun 2018
Canada trails US in patient access to rare disease therapies, CORD President says
6 June 2018 - Canada’s healthcare system is excellent for people with common ailments like diabetes or high blood pressure, ...